Related Experiment Video
Updated: Sep 21, 2025

Fluorescence-Based Measurements of Phosphatidylserine/Phosphatidylinositol 4-Phosphate Exchange Between Membranes
Published on: March 14, 2021
Membrane-bound O-acyltransferase 7 (MBOAT7)-driven phosphatidylinositol remodeling in advanced liver disease
Venkateshwari Varadharajan1, William J Massey1, J Mark Brown1
1Department of Cardiovascular and Metabolic Sciences, Lerner Research Institute Cleveland Clinic, Cleveland, OH, USA; Center for Microbiome and Human Health, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
Abstract:
Advanced liver diseases account for approximately 2 million deaths annually worldwide. Roughly, half of liver disease-associated deaths arise from complications of cirrhosis and the other half driven by viral hepatitis and hepatocellular carcinoma. Unfortunately, the development of therapeutic strategies to treat subjects with advanced liver disease has been hampered by a lack of mechanistic understanding of liver disease progression and a lack of human-relevant animal models. An important advance has been made within the past several years, as several genome-wide association studies have discovered that an SNP near the gene encoding membrane-bound O-acyltransferase 7 (MBOAT7) is associated with severe liver diseases. This common MBOAT7 variant (rs641738, C>T), which reduces MBOAT7 expression, confers increased susceptibility to nonalcoholic fatty liver disease, alcohol-associated liver disease, and liver fibrosis in patients chronically infected with viral hepatitis. Recent studies in mice also show that Mboat7 loss of function can promote hepatic steatosis, inflammation, and fibrosis, causally linking this phosphatidylinositol remodeling enzyme to liver health in both rodents and humans. Herein, we review recent insights into the mechanisms by which MBOAT7-driven phosphatidylinositol remodeling influences liver disease progression and discuss how rapid progress in this area could inform drug discovery moving forward.
Insights
A common genetic variant near the MBOAT7 gene is linked to severe liver diseases, including nonalcoholic fatty liver disease and cirrhosis. This variant reduces MBOAT7 expression, impacting liver health and disease progression.
Area of Science:
- Hepatology
- Genetics
- Molecular Biology
Background:
- Advanced liver diseases cause millions of deaths globally, often from cirrhosis, viral hepatitis, and hepatocellular carcinoma.
- Developing effective treatments is challenging due to limited understanding of disease mechanisms and lack of human-relevant models.
- Genome-wide association studies identified a single nucleotide polymorphism (SNP) near the MBOAT7 gene associated with severe liver conditions.
Purpose of the Study:
- To review recent findings on the role of MBOAT7 in liver disease.
- To explore the mechanistic link between MBOAT7-driven phosphatidylinositol remodeling and liver disease progression.
- To discuss the implications for future drug discovery in advanced liver diseases.
Main Methods:
- Review of recent scientific literature and genome-wide association studies.
- Analysis of genetic associations between MBOAT7 variants and liver disease susceptibility.
- Examination of preclinical studies in mouse models investigating Mboat7 loss of function.
Main Results:
- A common MBOAT7 variant (rs641738, C>T) reduces MBOAT7 expression and increases susceptibility to nonalcoholic fatty liver disease, alcohol-associated liver disease, and viral hepatitis-associated fibrosis.
- Loss of Mboat7 function in mice promotes hepatic steatosis, inflammation, and fibrosis.
- MBOAT7 is causally linked to liver health in both rodents and humans through phosphatidylinositol remodeling.
Conclusions:
- MBOAT7 plays a critical role in maintaining liver health, and its reduced expression is a risk factor for various severe liver diseases.
- Understanding MBOAT7's function in phosphatidylinositol remodeling offers new mechanistic insights into liver disease pathogenesis.
- Targeting MBOAT7 or related pathways presents a promising avenue for developing novel therapeutic strategies for advanced liver diseases.
More Related Videos
08:07Identification of Inositol Phosphate or Phosphoinositide Interacting Proteins by Affinity Chromatography Coupled to Western Blot or Mass Spectrometry
Published on: July 26, 2019
07:03Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss
Published on: July 19, 2024
Related Concept Videos
Phosphoinositides and PIPs
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
Synthesis of Phosphatidylcholine in the ER Membrane
The major components of all eukaryotic cell...
Lipids as Anchors
The carboxy-terminal of most of the prenylated proteins, such as Ras proteins, contains...
Assembly of the Lipid Bilayer in the ER
A large chunk of any biological membrane is composed of phospholipids. These lipids have a heterogeneous distribution across different subcellular organelles and even between...
Asymmetric Lipid Bilayer
GPI Anchoring of Proteins in the ER Membrane
GPI-anchor structure
A sequence of 11 enzymatic reactions results in the synthesis of the complete GPI anchor consisting of a hydrophobic and a hydrophilic portion. The hydrophobic portion comprises phosphatidylinositol, while the hydrophilic part comprises polar groups like phosphoethanolamine,...